Compare VLY & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VLY | PRAX |
|---|---|---|
| Founded | 1927 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 7.1B |
| IPO Year | 1994 | 2020 |
| Metric | VLY | PRAX |
|---|---|---|
| Price | $14.17 | $374.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 15 |
| Target Price | $14.65 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 6.4M | 412.1K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.31% | N/A |
| EPS Growth | ★ 46.38 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.58 | N/A |
| Revenue Next Year | $8.51 | $7,758.26 |
| P/E Ratio | $24.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.64 | $37.25 |
| 52 Week High | $15.20 | $392.70 |
| Indicator | VLY | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 39.67 | 60.36 |
| Support Level | $13.30 | $291.44 |
| Resistance Level | $15.00 | N/A |
| Average True Range (ATR) | 0.29 | 20.08 |
| MACD | -0.07 | 1.86 |
| Stochastic Oscillator | 12.05 | 83.46 |
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.